scholarly journals Evaluation of NLR Family CARD Domain Containing 3 and NLR Family CARD Domain Containing 5 Gene Expression in Interferon Gamma–Treated Mesenchymal Stem Cells from Wharton’s Jelly of Human Umbilical Cord

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Aida Nahumi ◽  
Leila Pirdel ◽  
Asadollah Asadi ◽  
Arash Abdolmaleki
Keyword(s):  
Gene Expression ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Interferon Gamma ◽  
Wharton’S Jelly ◽  
Human Umbilical Cord ◽  
Wharton's Jelly ◽  
Card Domain ◽  
Ifn Γ

Background: Human umbilical cord Wharton’s jelly has provided a new source for mesenchymal stem cells (MSCs). The highly proliferative capacity with low immunogenicity and multi-differentiation potential of its stem cells make them applicable for transplantation purposes. Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) play various roles in antigen presentation of pathogens and damaged cells to suppress and/or modulate inflammation. Objectives: In this study, the expression levels of NLR family CARD domain containing 3 (NLRC3) and NLRC5 genes were analyzed and compared in both untreated and interferon gamma (IFN-γ)–treated Wharton’s jelly-derived MSCs (WJ-MSCs). Methods: MSCs were isolated from human umbilical cord Wharton’s jelly using standard tissue culture. The expression of NLRC5 and NLRC3 genes was analyzed in IFN-γ–treated WJ-MSCs (24 hours after treatment) and untreated WJ-MSCs (as a control) using quantitative real-time polymerase chain reaction (PCR). Results: It was found that IFN-γ treatment mimicking an inflammation scenario led to a statistically significant increase of NLRC3 and NLRC5 gene expression compared to untreated WJ-MSCs (P ≤ 0.05). Conclusions: It seems that higher expression of NLRC3 and NLRC5 genes in treated WJ-MSCs may make them a proper candidate to be used as a source for cell therapy in inflammatory conditions.

Differential Expression of Osteogenic Differentiation in Human Umbilical Cord Wharton’s Jelly-Derived Mesenchymal Stem Cells Treated with Demineralized Bone

2008 ◽  
Vol 55-57 ◽  
pp. 697-700 ◽  
Author(s):  
D. Dhitiseith ◽  
S. Honsawek
Keyword(s):  
Gene Expression ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Wharton’S Jelly ◽  
Human Umbilical Cord ◽  
Activity Assay ◽  
Rt Pcr ◽  
Wharton's Jelly ◽  
Osteogenic Lineage

Mesenchymal stem cells are multipotential cells capable of differentiating into osteoblasts, chondrocytes, adipocytes, tenocytes, and myoblasts. Wharton’s jelly consists of stem cells that are a rich source of primitive multipotent mesenchymal cells. Demineralized bone matrix (DBM) has been widely utilized as a biomaterial to promote new bone formation. We isolate and characterize umbilical cord Wharton’s Jelly-derived mesenchymal stem (UCMS) cells derived from Wharton’s jelly and examine the biological activity of DBM in this cell line. Osteoblast differentiation of the UCMS cells was determined using alkaline phosphatase (ALP) activity assay. To examine differential gene expression during osteogenic differentiation, total RNA was isolated from UCMS cells in the absence or presence of DBM on day7 and analyzed using osteogenesis cDNA gene array. The selected genes were verified using reverse transcriptase-polymerase chain reaction (RT-PCR) analyses. Wharton’s jelly derived cells could differentiate along an osteogenic lineage after treatment of DBM. The ALP activity assay showed that human UCMS cells could differentiate into osteogenic lineage. Gene expression of human UCMS cells treated with DBM for 7 days was analyzed by using cDNA array and RT-PCR analyses. We found that expression of RUNX2 and SMAD2 was upregulated whereas SMAD7 expression was downregulated as confirmed by RT-PCR. UCMS cells from a Wharton’s jelly of human umbilical cord could express osteogenesis genes for treatment with DBM. Wharton’s jelly from umbilical cord is a new source of mesenchymal stem cells that are readily available for application to bone tissue engineering.

scholarly journals Exosomes derived from human umbilical cord Wharton's jelly mesenchymal stem cells ameliorate experimental lymphedema

2021 ◽  
Vol 11 (7) ◽  
Author(s):  
Zhao Ting ◽  
Yan Zhi‐xin ◽  
Tan You‐wen ◽  
Yang Fu‐ji ◽  
Sun Hui ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Wharton’S Jelly ◽  
Human Umbilical Cord ◽  
Wharton's Jelly

scholarly journals Enhanced Chondrogenic Differentiation of Human Umbilical Cord Wharton's Jelly Derived Mesenchymal Stem Cells by GSK-3 Inhibitors

PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0168059 ◽  
Author(s):  
Prapot Tanthaisong ◽  
Sumeth Imsoonthornruksa ◽  
Apichart Ngernsoungnern ◽  
Piyada Ngernsoungnern ◽  
Mariena Ketudat-Cairns ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Chondrogenic Differentiation ◽  
Wharton’S Jelly ◽  
Human Umbilical Cord ◽  
Wharton's Jelly

scholarly journals Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton’s jelly

2012 ◽  
Vol 48 (2) ◽  
pp. 75-83 ◽  
Author(s):  
Parvin Salehinejad ◽  
Noorjahan Banu Alitheen ◽  
Abdul Manaf Ali ◽  
Abdul Rahman Omar ◽  
Maryam Mohit ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Wharton’S Jelly ◽  
Human Umbilical Cord ◽  
Wharton's Jelly

scholarly journals Isolation and Characterisation of Mesenchymal Stem Cells from Different Regions of the Human Umbilical Cord

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Claire Mennan ◽  
Karina Wright ◽  
Atanu Bhattacharjee ◽  
Birender Balain ◽  
James Richardson ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Wharton’S Jelly ◽  
Ethical Consideration ◽  
Human Umbilical Cord ◽  
Cell Therapies ◽  
Wharton's Jelly ◽  
Umbilical Cords

Umbilical cords as a source of stem cells are of increasing interest for cell therapies as they present little ethical consideration and are reported to contain immune privileged cells which may be suitable for allogeneic based therapies. Mesenchymal stem cells (MSCs) sourced from several different cord regions, including artery, vein, cord lining, and Wharton’s jelly, are described in the literature. However, no one study has yet isolated and characterised MSCs from all regions of the same cord to determine the most suitable cells for cell based therapeutics.

Sign in / Sign up

Export Citation Format

Share Document